1
|
Carzaniga T, Casiraghi L, Nava G, Zanchetta G, Inzani T, Chiari M, Bollati V, Epis S, Bandi C, Lai A, Zehender G, Bellini T, Buscaglia M. Serum antibody fingerprinting of SARS-CoV-2 variants in infected and vaccinated subjects by label-free microarray biosensor. Front Immunol 2024; 15:1323406. [PMID: 38476234 PMCID: PMC10927789 DOI: 10.3389/fimmu.2024.1323406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 02/06/2024] [Indexed: 03/14/2024] Open
Abstract
Both viral infection and vaccination affect the antibody repertoire of a person. Here, we demonstrate that the analysis of serum antibodies generates information not only on the virus type that caused the infection but also on the specific virus variant. We developed a rapid multiplex assay providing a fingerprint of serum antibodies against five different SARS-CoV-2 variants based on a microarray of virus antigens immobilized on the surface of a label-free reflectometric biosensor. We analyzed serum from the plasma of convalescent subjects and vaccinated volunteers and extracted individual antibody profiles of both total immunoglobulin Ig and IgA fractions. We found that Ig level profiles were strongly correlated with the specific variant of infection or vaccination and that vaccinated subjects displayed a larger quantity of total Ig and a lower fraction of IgA relative to the population of convalescent unvaccinated subjects.
Collapse
Affiliation(s)
- Thomas Carzaniga
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Luca Casiraghi
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Giovanni Nava
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Giuliano Zanchetta
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Tommaso Inzani
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Marcella Chiari
- Istituto di Scienze e Tecnologie Chimiche “Giulio Natta”, National Research Council of Italy (SCITEC-CNR), Milano, Italy
| | - Valentina Bollati
- Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milano, Italy
| | - Sara Epis
- Dipartimento di Bioscienze and Pediatric Clinical Research Center (CRC) ‘Fondazione Romeo ed Enrica Invernizzi’, Università degli Studi di Milano, Milano, Italy
| | - Claudio Bandi
- Dipartimento di Bioscienze and Pediatric Clinical Research Center (CRC) ‘Fondazione Romeo ed Enrica Invernizzi’, Università degli Studi di Milano, Milano, Italy
| | - Alessia Lai
- Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milano, Italy
| | - Gianguglielmo Zehender
- Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milano, Italy
| | - Tommaso Bellini
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| | - Marco Buscaglia
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
2
|
Khelil MM. Six Sigma driven QC in antibody testing for infectious diseases. Clin Chem Lab Med 2024; 62:e40-e43. [PMID: 37559170 DOI: 10.1515/cclm-2023-0552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 07/20/2023] [Indexed: 08/11/2023]
Affiliation(s)
- Mohamed Mokhtar Khelil
- Clinical Immunology and Clinical Molecular Biology Laboratory, Pasteur Institute of Algeria, Annexe of M'SILA, Alger, Algeria
| |
Collapse
|
3
|
Wei Z, Angrisano F, Eriksson EM, Mazhari R, Van H, Zheng S, Center RJ, Boo I, McMahon J, Lau J, Kiernan‐Walker N, Ruybal‐Pesántez S, Mueller I, Robinson LJ, Anderson DA, Drummer HE. Serological assays to measure dimeric IgA antibodies in SARS-CoV-2 infections. Immunol Cell Biol 2023; 101:857-866. [PMID: 37593973 PMCID: PMC10952984 DOI: 10.1111/imcb.12682] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 05/22/2023] [Accepted: 08/01/2023] [Indexed: 08/19/2023]
Abstract
Current serological tests cannot differentiate between total immunoglobulin A (IgA) and dimeric IgA (dIgA) associated with mucosal immunity. Here, we describe two new assays, dIgA-ELISA and dIgA-multiplex bead assay (MBA), that utilize the preferential binding of dIgA to a chimeric form of secretory component, allowing the differentiation between dIgA and monomeric IgA. dIgA responses elicited through severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were measured in (i) a longitudinal panel, consisting of 74 samples (n = 20 individuals) from hospitalized cases of coronavirus disease 2019 (COVID-19); (ii) a longitudinal panel, consisting of 96 samples (n = 10 individuals) from individuals with mild COVID-19; (iii) a cross-sectional panel with PCR-confirmed SARS-CoV-2 infection with mild COVID-19 (n = 199) and (iv) pre-COVID-19 samples (n = 200). The dIgA-ELISA and dIgA-MBA demonstrated a specificity for dIgA of 99% and 98.5%, respectively. Analysis of dIgA responses in the longitudinal panels revealed that 70% (ELISA) and 50% (MBA) of patients elicited a dIgA response by day 20 after PCR diagnosis with a SARS-CoV-2 infection. Individuals with mild COVID-19 displayed increased levels of dIgA within the first 3 weeks after diagnosis but responses appeared to be short lived, compared with sustained IgA levels. However, in samples from hospitalized patients with COVID-19 we observed high and sustained levels of dIgA, up to 245 days after PCR diagnosis. Our results suggest that severe COVID-19 infections are associated with sustained levels of plasma dIgA compared with mild cases.
Collapse
Affiliation(s)
- Zihui Wei
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - Fiona Angrisano
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - Emily M Eriksson
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
- The University of MelbourneDepartment of Medical BiologyParkvilleVIC3052Australia
| | - Ramin Mazhari
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
- The University of MelbourneDepartment of Medical BiologyParkvilleVIC3052Australia
| | - Huy Van
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - Shuning Zheng
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - Rob J Center
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
- Peter Doherty Institute for Infection and Immunity at The University of MelbourneParkvilleVIC3052Australia
| | - Irene Boo
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - James McMahon
- Monash UniversityDepartment of Infectious Diseases Alfred HealthMelbourneVIC3004Australia
| | - Jillian Lau
- Peter Doherty Institute for Infection and Immunity at The University of MelbourneParkvilleVIC3052Australia
- Monash UniversityDepartment of Infectious Diseases Alfred HealthMelbourneVIC3004Australia
| | - Nicholas Kiernan‐Walker
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
| | - Shazia Ruybal‐Pesántez
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
- The University of MelbourneDepartment of Medical BiologyParkvilleVIC3052Australia
| | - Ivo Mueller
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
| | - Leanne J Robinson
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
- Walter and Eliza Hall Institute of Medical Research Department of Population Health and ImmunityParkvilleVIC3052Australia
| | - David A Anderson
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
| | - Heidi E Drummer
- Burnet Institute, 85 Commercial RoadDepartment of Life SciencesMelbourneVIC3004Australia
- Peter Doherty Institute for Infection and Immunity at The University of MelbourneParkvilleVIC3052Australia
- Monash UniversityDepartment of MicrobiologyClaytonVIC3168Australia
| |
Collapse
|
4
|
Lira-Amaya JJ, Beristain-Ruiz DM, Racanco-Delgado J, Garza-Hernández JA, Vital-García C, Santamaria-Espinosa M, Martínez-García G, Alvarez-Martínez A, Quezada-Casasola A, Rojas-Martínez C, Alvarado-Robles B, Figueroa-Millán JV. Molecular Detection and Characterization of Ehrlichia canis Isolates from Three Geographic Regions in Mexico: A Retrospective Study. Life (Basel) 2023; 13:1629. [PMID: 37629486 PMCID: PMC10456115 DOI: 10.3390/life13081629] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 07/24/2023] [Accepted: 07/26/2023] [Indexed: 08/27/2023] Open
Abstract
Canine monocytic ehrlichiosis (CME) is the most common tick-borne disease affecting domestic dogs and other wild canids. It has a worldwide distribution and is associated with the presence of the brown dog tick. Few studies have been conducted in Mexico to identify and characterize Ehrlichia canis genetic variability. In the present study, 111 dogs of different sex, breed, and age from three geographic regions in Mexico were included. All of them had a previous history of tick infestation and/or the presence of one or more clinical signs compatible with CME. All dogs were tested by a commercial ELISA and nested PCR assay for the detection of E. canis. In addition, we analyzed the E. canis genetic diversity from the 16S rRNA gene sequences obtained in this study, along with 15 additional sequences described for E. canis in Mexico and obtained from GeneBank. Serological detection by commercial ELISA results showed overall infection rates of 85.58% (95/111), including 73.1% (30/41) in samples from Guerrero state; 75% (15/20) in Morelos; and 100% (50/50) in Chihuahua. On the other hand, molecular detection (nPCR assay) showed 31.5% (35/111) overall infection rate, with 41.4% (17/41) in Guerrero state; 55% (11/20) in Morelos; and 14% (7/50) in Chihuahua. We observed a high 16S rRNA gene sequence conservancy in most of the E. canis isolates in the three geographical areas from Mexico, including those analyzed in this research, suggesting a common geographic origin among isolates.
Collapse
Affiliation(s)
- José Juan Lira-Amaya
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| | - Diana M. Beristain-Ruiz
- Departamento de Ciencias Veterinarias, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente y Estocolmo s/n Colonia Progresista AP 1729-D Cd., Ciudad Juárez 32310, Chihuahua, Mexico; (D.M.B.-R.); (C.V.-G.); (A.Q.-C.); (B.A.-R.)
| | - Jesús Racanco-Delgado
- Unidad Académica de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Guerrero, Km. 3.5, de la Carretera Altamirano-Iguala, Ciudad Altamirano 39640, Guerrero, Mexico;
| | - Javier A. Garza-Hernández
- Departamento de Ciencias Químico-Biológicas, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente y Estocolmo s/n Colonia Progresista, Ciudad Juárez 32310, Chihuahua, Mexico;
| | - Cuauhcihuatl Vital-García
- Departamento de Ciencias Veterinarias, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente y Estocolmo s/n Colonia Progresista AP 1729-D Cd., Ciudad Juárez 32310, Chihuahua, Mexico; (D.M.B.-R.); (C.V.-G.); (A.Q.-C.); (B.A.-R.)
| | - Montserrat Santamaria-Espinosa
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| | - Grecia Martínez-García
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| | - Antonio Alvarez-Martínez
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| | - Andrés Quezada-Casasola
- Departamento de Ciencias Veterinarias, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente y Estocolmo s/n Colonia Progresista AP 1729-D Cd., Ciudad Juárez 32310, Chihuahua, Mexico; (D.M.B.-R.); (C.V.-G.); (A.Q.-C.); (B.A.-R.)
| | - Carmen Rojas-Martínez
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| | - Beatriz Alvarado-Robles
- Departamento de Ciencias Veterinarias, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente y Estocolmo s/n Colonia Progresista AP 1729-D Cd., Ciudad Juárez 32310, Chihuahua, Mexico; (D.M.B.-R.); (C.V.-G.); (A.Q.-C.); (B.A.-R.)
| | - Julio V. Figueroa-Millán
- CENID-Salud Animal e Inocuidad, INIFAP, Carretera Cuernavaca-Cuautla No. 8534, Jiutepec 62550, Morelos, Mexico; (J.J.L.-A.); (M.S.-E.); (G.M.-G.); (A.A.-M.); (C.R.-M.)
| |
Collapse
|
5
|
Badrick T. Letter to the Editor regarding the article by Wayne J. Dimech et al. Time to address quality control processes applied to antibody testing for infectious diseases. Clin Chem Lab Med 2023; 61(2):205-212. Clin Chem Lab Med 2023; 61:e135-e136. [PMID: 36866704 DOI: 10.1515/cclm-2023-0118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 02/10/2023] [Indexed: 03/04/2023]
Affiliation(s)
- Tony Badrick
- RCPA Quality Assurance Programs, Sydney, Australia
| |
Collapse
|
6
|
Ma X, Li Z, Whelan MG, Kim D, Cao C, Yanes-Lane M, Yan T, Jaenisch T, Chu M, Clifton DA, Subissi L, Bobrovitz N, Arora RK. Serology Assays Used in SARS-CoV-2 Seroprevalence Surveys Worldwide: A Systematic Review and Meta-Analysis of Assay Features, Testing Algorithms, and Performance. Vaccines (Basel) 2022; 10. [PMID: 36560415 DOI: 10.3390/vaccines10122000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 11/21/2022] [Accepted: 11/21/2022] [Indexed: 11/26/2022] Open
Abstract
Background: Many serological assays to detect SARS-CoV-2 antibodies were developed during the COVID-19 pandemic. Differences in the detection mechanism of SARS-CoV-2 serological assays limited the comparability of seroprevalence estimates for populations being tested. Methods: We conducted a systematic review and meta-analysis of serological assays used in SARS-CoV-2 population seroprevalence surveys, searching for published articles, preprints, institutional sources, and grey literature between 1 January 2020, and 19 November 2021. We described features of all identified assays and mapped performance metrics by the manufacturers, third-party head-to-head, and independent group evaluations. We compared the reported assay performance by evaluation source with a mixed-effect beta regression model. A simulation was run to quantify how biased assay performance affects population seroprevalence estimates with test adjustment. Results: Among 1807 included serosurveys, 192 distinctive commercial assays and 380 self-developed assays were identified. According to manufacturers, 28.6% of all commercial assays met WHO criteria for emergency use (sensitivity [Sn.] >= 90.0%, specificity [Sp.] >= 97.0%). However, manufacturers overstated the absolute values of Sn. of commercial assays by 1.0% [0.1, 1.4%] and 3.3% [2.7, 3.4%], and Sp. by 0.9% [0.9, 0.9%] and 0.2% [−0.1, 0.4%] compared to third-party and independent evaluations, respectively. Reported performance data was not sufficient to support a similar analysis for self-developed assays. Simulations indicate that inaccurate Sn. and Sp. can bias seroprevalence estimates adjusted for assay performance; the error level changes with the background seroprevalence. Conclusions: The Sn. and Sp. of the serological assay are not fixed properties, but varying features depending on the testing population. To achieve precise population estimates and to ensure the comparability of seroprevalence, serosurveys should select assays with high performance validated not only by their manufacturers and adjust seroprevalence estimates based on assured performance data. More investigation should be directed to consolidating the performance of self-developed assays.
Collapse
|
7
|
Dainese C, Valeri F, Bardetta M, Sella C, Porreca A, Valpreda A, Pittaluga F, Mengozzi G, Bruno B, Borchiellini A. Impact of COVID-19 Infection, Vaccination, and Serological Response in Immune Thrombocytopenic Purpura Patients: A Single-Center Global Analysis. Biomedicines 2022; 10:2674. [PMID: 36359194 PMCID: PMC9687178 DOI: 10.3390/biomedicines10112674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Revised: 10/17/2022] [Accepted: 10/20/2022] [Indexed: 11/17/2023] Open
Abstract
Both SARS-CoV-2 infection and vaccination have raised concern in immune-mediated diseases, including immune thrombocytopenic purpura (ITP) considering risk of de novo ITP development and ITP recurrence. Here, we report on data from a single-center retrospective-prospective collection aiming to evaluate platelet (plt) dynamics in patients (pts) with chronic ITP after COVID-19 infection (before and after vaccination) and after the first, second and third vaccine doses. Furthermore, we analyzed the serological response after the first two doses of COVID-19 vaccination. A total of 64 pts currently followed for chronic ITP who experienced COVD-19 infection and/or vaccination with an available plt count before and after such events were included in the analysis. A low incidence of ITP exacerbation following vaccine sessions (6-16%) was observed in comparison with a high frequency of exacerbation and rescue treatment necessity after COVID-19 infection in unvaccinated pts (83%). Moreover, the lower ITP exacerbation rate observed in infected pts previously vaccinated (18%) suggests further protective effects in this population. Finally, a high seroconversion rate was observed, confirming data reported in previously published studies on immune cytopenia and rheumatological diseases, but more evidence is awaited to establish the clinical impact of serological response.
Collapse
Affiliation(s)
- Cristina Dainese
- Regional Reference Center for Thrombotic and Haemorrhagic Disorders of the Adult, Department of Hematology and Oncology, Hematology Divison, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Federica Valeri
- Regional Reference Center for Thrombotic and Haemorrhagic Disorders of the Adult, Department of Hematology and Oncology, Hematology Divison, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Marco Bardetta
- Regional Reference Center for Thrombotic and Haemorrhagic Disorders of the Adult, Department of Hematology and Oncology, Hematology Divison, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Carola Sella
- Regional Reference Center for Thrombotic and Haemorrhagic Disorders of the Adult, Department of Hematology and Oncology, Hematology Divison, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Annamaria Porreca
- Department of Medical, Oral and Biotechnologies Sciences, University of Chieti-Pescara, 66100 Chieti, Italy
| | - Alessandra Valpreda
- Clinical Biochemistry Laboratory, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Fabrizia Pittaluga
- Laboratory of Microbiology and Virology, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Giulio Mengozzi
- Clinical Biochemistry Laboratory, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| | - Benedetto Bruno
- Hematology Division, Department of Hematology and Oncology, Azienda Ospedaliera Città della Salute e della Scienza di Torino-Molinette, 10126 Turin, Italy
| | - Alessandra Borchiellini
- Regional Reference Center for Thrombotic and Haemorrhagic Disorders of the Adult, Department of Hematology and Oncology, Hematology Divison, University Hospital City of Science and Health Molinette, 10126 Turin, Italy
| |
Collapse
|
8
|
Bagno FF, Sérgio SAR, Figueiredo MM, Godoi LC, Andrade LAF, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AGP, Durigon EL, Gazzinelli RT, Teixeira SMR, Fernandes APSM, da Fonseca FG. DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19. J Clin Virol Plus 2022:100103. [PMID: 35993012 PMCID: PMC9384617 DOI: 10.1016/j.jcvp.2022.100103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 08/01/2022] [Accepted: 08/12/2022] [Indexed: 11/28/2022] Open
Abstract
There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in E. coli. Using a total of 894 clinical samples we showed that the rN-ELISA was able to detect IgG antibodies against SARS-CoV-2 with high sensitivity (97.5%) and specificity (96.3%) when compared to a commercial antibody test. After three external validation studies, we showed that the test accuracy was higher than 90%. The rN-ELISA IgG kit constitutes a convenient and specific method for the large-scale determination of SARS-CoV-2 antibodies in human sera with high reliability.
Collapse
Affiliation(s)
- Flávia F Bagno
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
| | - Sarah A R Sérgio
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
| | - Maria Marta Figueiredo
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Universidade Estadual de Minas Gerais, Divinópolis, MG, Brazil
| | - Lara C Godoi
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
| | - Luis A F Andrade
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
| | - Natália C Salazar
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
| | - Camila P Soares
- Universidade de São Paulo (USP), Instituto de Ciências Biomédicas, São Paulo, SP, Brazil
| | - Andressa Aguiar
- Geriatric and Convalescent Hospital Dom Pedro II, São Paulo, SP, Brazil
| | - Flávia Jaqueline Almeida
- Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP, Brazil
| | - Edimilson D da Silva
- Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
| | - Antônio G P Ferreira
- Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
| | - Edison Luiz Durigon
- Universidade de São Paulo (USP), Instituto de Ciências Biomédicas, São Paulo, SP, Brazil
| | - Ricardo T Gazzinelli
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Fundação Oswaldo Cruz-Fiocruz, Centro de Pesquisas René Rachou, Belo Horizonte, MG, Brazil
| | - Santuza M R Teixeira
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Universidade Federal de Minas Gerais, Depto de Bioquímica e Imunologia, Belo Horizonte, MG, Brazil
| | - Ana Paula S M Fernandes
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Universidade Federal de Minas Gerais, Faculdade de Farmácia, Belo Horizonte, MG, Brazil
| | - Flavio G da Fonseca
- Centro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil
- Universidade Federal de Minas Gerais, Depto de Microbiologia, ICB/UFMG, Belo Horizonte, MG, Brazil
| |
Collapse
|
9
|
Fujigaki H, Yamamoto Y, Koseki T, Banno S, Ando T, Ito H, Fujita T, Naruse H, Hata T, Moriyama S, Takahashi Y, Suzuki T, Murakami T, Yoshida Y, Yagura Y, Oyamada T, Takemura M, Kondo M, Iwata M, Saito K. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Microbiol Spectr 2022; 10:e0118121. [PMID: 35044205 PMCID: PMC8768797 DOI: 10.1128/spectrum.01181-21] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Accepted: 12/21/2021] [Indexed: 12/23/2022] Open
Abstract
To fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine efficacy, we analyzed the levels of IgG, IgM, and IgA against the receptor-binding domain (RBD) of SARS-CoV-2 in the sera from BNT162b2 vaccinated individuals in Japan. This study included 219 individuals who received two doses of BNT162b2. The levels of IgG, IgM, and IgA against RBD were measured by enzyme-linked immunosorbent assay before and after the first and second vaccination, respectively. The relationship between antibody levels and several factors, including age, gender, and hypertension were analyzed. Virus-neutralizing activity in sera was measured to determine the correlation with the levels of antibodies. A chemiluminescent enzyme immunoassay (CLEIA) method to measure IgG against RBD was developed and validated for the clinical setting. The levels of all antibody isotypes were increased after vaccination. Among them, RBD-IgG was dramatically increased after the second vaccination. The IgG levels in females were significantly higher than in males. There was a negative correlation between age and IgG levels in males. The IgG levels significantly correlated with the neutralizing activity. The CLEIA assay measuring IgG against RBD showed a reliable performance and a high correlation with neutralizing activity. Monitoring of IgG against RBD is a powerful tool to predict the efficacy of SARS-CoV-2 vaccination and provides useful information in considering a personalized vaccination strategy for COVID-19. IMPORTANCE Mass vaccination campaigns using mRNA vaccines against SARS-CoV-2 have begun in many countries. Serological assays to detect antibody production may be a useful tool to monitor the efficacy of SARS-CoV-2 vaccination in individuals. Here, we reported the induction of antibody isotype responses after the first and second dose of the BNT162b2 vaccine in a well-defined cohort of employees in Japan. We also reported that age, gender, and hypertension are associated with differences in antibody response after vaccination. This study not only provides valuable information with respect to antibody responses after BNT162b2 vaccination in the Japanese population but also the usefulness of serological assays for monitoring vaccine efficacy in clinical laboratories to determine a personalized vaccination strategy for COVID-19.
Collapse
Affiliation(s)
- Hidetsugu Fujigaki
- Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| | - Yasuko Yamamoto
- Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| | - Takenao Koseki
- Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
- Center for Clinical Trial and Research Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Sumi Banno
- Center for Clinical Trial and Research Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Tatsuya Ando
- Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Hiroyasu Ito
- Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Takashi Fujita
- Department of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Aichi, Japan
| | - Hiroyuki Naruse
- Department of Medical Laboratory Science, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| | - Tadayoshi Hata
- Department of Medical Laboratory Science, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| | - Saya Moriyama
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan
| | - Yoshimasa Takahashi
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan
| | - Tadaki Suzuki
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan
| | - Takahiro Murakami
- Diagnostics Research Laboratories, Diagnostics Technical Service & Research Operations, Diagnostics Division, FUJIFILM Wako Pure Chemical Corporation, Amagasaki, Hyogo, Japan
| | - Yukihiro Yoshida
- Diagnostics Research Laboratories, Diagnostics Technical Service & Research Operations, Diagnostics Division, FUJIFILM Wako Pure Chemical Corporation, Amagasaki, Hyogo, Japan
| | - Yo Yagura
- Diagnostics Research Laboratories, Diagnostics Technical Service & Research Operations, Diagnostics Division, FUJIFILM Wako Pure Chemical Corporation, Amagasaki, Hyogo, Japan
| | | | - Masao Takemura
- Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| | - Masashi Kondo
- Center for Clinical Trial and Research Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Mitsunaga Iwata
- Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - Kuniaki Saito
- Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
| |
Collapse
|
10
|
Gupta R, Gupta P, Wang Z, Seth A, Morrissey J, George I, Gandra S, Storch G, Parikh B, Genin G, Singamaneni S. Plasmon-enhanced Quantitative Lateral Flow Assay for Femtomolar Detection of SARS-CoV-2 Antibodies and Antigens. Res Sq 2022:rs.3.rs-1258688. [PMID: 35194598 PMCID: PMC8863156 DOI: 10.21203/rs.3.rs-1258688/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Lateral flow assays (LFAs) are the cornerstone of point-of-care diagnostics. Although rapid and inexpensive, they are 1000-fold less sensitive than laboratory-based tests and cannot be used for definitive negative diagnosis. Here, we overcome this fundamental limitation by employing plasmonically-enhanced nanoscale colorimetric and fluorescent labels. Plasmonic LFAs (p-LFAs) enabled ultrasensitive detection and quantification of low abundance analytes, without compromising the direct visual detection of conventional LFAs. Dynamic ranges and limits of detection were up to 100-fold superior to "gold standard" ELISA (enzyme-linked immunosorbent assay). p-LFAs had sample-to-answer time of 20 min, compared to 4 hours for ELISA, while achieving over 95% analytical sensitivity and 100% analytical specificity for antibodies and antigens of SARS-CoV-2 in human specimens. We also demonstrate that the p-LFAs enable quantitative detection of the target analytes in a standard-free manner. p-LFAs offer potential as a broadly adaptable point-of-care diagnostic platform that outperforms standard laboratory tests in sensitivity, speed, dynamic range, ease of use, and cost.
Collapse
|
11
|
Kumar G, Sterrett S, Hall L, Tabengwa E, Honjo K, Larimer M, Davis RS, Goepfert PA, Larimer BM. Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. Protein Eng Des Sel 2022; 35:6529796. [PMID: 35174857 PMCID: PMC9005051 DOI: 10.1093/protein/gzab033] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 11/30/2021] [Accepted: 06/16/2021] [Indexed: 11/12/2022] Open
Abstract
Quantification of the anti-SARS-CoV-2 antibody response has proven to be a prominent diagnostic tool during the COVID-19 pandemic. Antibody measurements have aided in the determination of humoral protection following infection or vaccination and will likely be essential for predicting the prevalence of population level immunity over the next several years. Despite widespread use, current tests remain limited in part, because antibody capture is accomplished through the use of complete spike and nucleocapsid proteins that contain significant regions of overlap with common circulating coronaviruses. To address this limitation, a unique epitope display platform utilizing monovalent display and protease-driven capture of peptide epitopes was used to select high affinity peptides. A single round of selection using this strategy with COVID-19 positive patient plasma samples revealed surprising differences and specific patterns in the antigenicity of SARS-CoV-2 proteins, especially the spike protein. Putative epitopes were assayed for specificity with convalescent and control samples, and the individual binding kinetics of peptides were also determined. A subset of prioritized peptides was used to develop an antibody diagnostic assay that showed low cross reactivity while detecting 37% more positive antibody cases than a gold standard FDA EUA test. Finally, a subset of peptides were compared with serum neutralization activity to establish a 2 peptide assay that strongly correlates with neutralization. Together, these data demonstrate a novel phage display method that is capable of comprehensively and rapidly mapping patient viral antibody responses and selecting high affinity public epitopes for the diagnosis of humoral immunity.
Collapse
Affiliation(s)
- Garima Kumar
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA,O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Sarah Sterrett
- Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Lucinda Hall
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Edlue Tabengwa
- Multidisciplinary Molecular Interaction Core, Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Kazuhito Honjo
- Department of Medicine, Microbiology, and Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | | | - Randall S Davis
- Department of Medicine, Microbiology, and Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Paul A Goepfert
- Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | | |
Collapse
|
12
|
Moyet J, Helle F, Bourdenet G, Joseph C, Gubler B, Deschasse G, Defouilloy I, Slovenski T, François C, Liabeuf S, Schmit JL, Lanoix JP, Castelain S, Bloch F, Brochot E. Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities. J Nutr Health Aging 2022; 26:57-63. [PMID: 35067704 PMCID: PMC8683825 DOI: 10.1007/s12603-021-1713-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 11/15/2021] [Indexed: 12/02/2022]
Abstract
INTRODUCTION Elderly residents of nursing homes (NHs) and long-term care units (LTCUs) have been shown to have a high risk of mortality and morbidity in cases of SARS-CoV-2 infection. The objective of this study was to examine the kinetics of neutralizing antibodies (NAbs) directed against the SARS-CoV-2 virus in residents of the NH and LTCU units of our University Hospital who were identified with positive serology after the first epidemic outbreak. MATERIALS AND METHODS The participants included were sampled every three months for qualitative serological testing, as well as quantitative testing by neutralization tests using retroviral particles containing the S glycoprotein of SARS-CoV-2. Vaccination using the Comirnaty (Pfizer BNT162b2) vaccine begun before the last serological follow-up. RESULTS The median NAb titer in June 2020 was 80 [40; 60] versus 40 [40; 160] three months later, showing a statistically significant decline (p < 0.007), but remained stable between the three- and six-month timepoints (p = 0.867). By nine months after vaccination, we observed a significant difference between vaccinated residents known to have positive serology before vaccination (SERO+, Vacc+) and those vaccinated without having previously shown COVID-19 seroconversion (SERO-, Vacc+), the latter group showing similar titers to the SERO+, Vacc- participants (p=0.166). The median antibody titer in SERO+, Vacc+ patients increased 15-fold following vaccination. DISCUSSION Humoral immunity against SARS-CoV-2 appears to be persistent in elderly institutionalized patients, with a good post-vaccination response by residents who had already shown seroconversion but a notably diminished response by those who were seronegative before vaccination. To evaluate immunity in its entirety and elaborate a sound vaccination strategy, the cellular immune response via T cells specific to SARS-CoV-2 merits analysis, as this response is susceptible to being affected by immunosenescence.
Collapse
Affiliation(s)
- J Moyet
- Pr Frédéric Bloch, Department of Gerontology, University Hospital Amiens-Picardie - Hôpital Nord, Place Victor Pauchet - 80054 Amiens Cedex 1, France, Phone / Fax: +333.22.45.57.20 / +333. 22.45.53.30, E-mail: , ORCID identifier : 0000-0002-6046-7097
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Tarkowski M, de Jager W, Schiuma M, Covizzi A, Lai A, Gabrieli A, Corbellino M, Bergna A, Ventura CD, Galli M, Riva A, Antinori S. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Front Immunol 2021; 12:793191. [PMID: 34975897 PMCID: PMC8718396 DOI: 10.3389/fimmu.2021.793191] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 11/30/2021] [Indexed: 11/13/2022] Open
Abstract
Purpose To compare SARS-CoV-2 antigen-specific antibody production and plasma neutralizing capacity against B.1 wild-type-like strain, and Gamma/P.1 and Delta/B.1.617.2 variants-of-concern, in subjects with different Covid-19 disease and vaccination histories. Methods Adult subjects were: 1) Unvaccinated/hospitalized for Covid-19; 2) Covid-19-recovered followed by one BNT162b2 vaccine dose; and 3) Covid-19-naïve/2-dose BNT162b2 vaccinated. Multiplex Luminex® immunoassays measured IgG, IgA, and IgM plasma levels against SARS-CoV-2 receptor-binding domain (RBD), spike-1 (S), and nucleocapsid proteins. Neutralizing activity was determined in Vero E6 cytopathic assays. Results Maximum anti-RBD IgG levels were similar in Covid-19‑recovered individuals 8‒10 days after single-dose vaccination and in Covid-19-naïve subjects 7 days after 2nd vaccine dosing; both groups had ≈2‑fold higher anti-RBD IgG levels than Unvaccinated/Covid-19 subjects tracked through 2 weeks post-symptom onset. Anti-S IgG expression patterns were similar to RBD within each group, but with lower signal strengths. Viral antigen-specific IgA and IgM levels were more variable than IgG patterns. Anti-nucleocapsid immunoglobulins were not detected in Covid-19-naïve subjects. Neutralizing activity against the B.1 strain, and Gamma/P.1 and Delta/B.1.617.2 variants, was highest in Covid‑19-recovered/single-dose vaccinated subjects; although neutralization against the Delta variant in this group was only 26% compared to B.1 neutralization, absolute anti-Delta titers suggested maintained protection. Neutralizing titers against the Gamma and Delta variants were 33‒77% and 26‒67%, respectively, versus neutralization against the B.1 strain (100%) in the three groups. Conclusion These findings support SARS-CoV-2 mRNA vaccine usefulness regardless of Covid-19 history, and confirm remarkable protection provided by a single vaccine dose in people who have recovered from Covid-19.
Collapse
Affiliation(s)
- Maciej Tarkowski
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | | | - Marco Schiuma
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Alice Covizzi
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Alessia Lai
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Arianna Gabrieli
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Mario Corbellino
- Division of Infectious Diseases, Aziende Socio Sanitarie Territoriali (ASST) Fatebenefratelli Sacco Hospital, Milan, Italy
| | - Annalisa Bergna
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Carla Della Ventura
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Massimo Galli
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Agostino Riva
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Spinello Antinori
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
14
|
Pedersen K, Kristensen CS, Kvisgaard LK, Larsen LE. Impacts of Quarterly Sow Mass Vaccination with a Porcine Reproductive and Respiratory Syndrome Virus Type 1 (PRRSV-1) Modified Live Vaccine in Two Herds. Vaccines (Basel) 2021; 9:vaccines9101057. [PMID: 34696165 PMCID: PMC8537578 DOI: 10.3390/vaccines9101057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 09/16/2021] [Accepted: 09/18/2021] [Indexed: 11/16/2022] Open
Abstract
In recent years, there has been a considerable increase in the use of Modified Live PRRSV Vaccines (MLV) for mass vaccination in Denmark. The potential risks and negative impact of this strategy have been sparsely studied. The aim of this study was to investigate the impact of quarterly sow mass vaccination in two Danish sow herds. The study was performed as an observational prospective cohort of 120 sows in each of two commercial breeding herds in a paired design. Blood samples were taken from sows and oral fluid samples from nursery pigs (four to ten weeks old) before and after vaccination. The presence of PRRSV-1 RNA was measured by real time quantitative reverse transcription-polymerase chain reaction (RT-qPCR), and the level of PRRSV-1 specific antibodies was measured by two different serological assays. PRRS virus was not detected in the sow herds two days before and two weeks after vaccination, but the vaccine strain virus was detected in the nursery pigs. The prevalence of sows without antibodies towards PRRSV-1 went from 6-15% before vaccination to 1-4% after vaccination depending on the serological assay used, despite the fact that they had previously been repeatedly vaccinated. Four sows tested negative for antibodies in both assays after vaccination.
Collapse
Affiliation(s)
- Kasper Pedersen
- SEGES Danish Pig Research Centre, Agro Food Park 15V, 8200 Aarhus N, Denmark; (K.P.); (C.S.K.)
| | | | - Lise Kirstine Kvisgaard
- Faculty of Health and Medical Sciences, Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark;
| | - Lars Erik Larsen
- Faculty of Health and Medical Sciences, Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark;
- Correspondence:
| |
Collapse
|
15
|
Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, Yang HS, Hao Y, Sukhu A, Rand S, Chadburn A, Shi Y, Zuk R, Nussenzweig MC, Cushing MM, Zhao Z. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem 2021; 67:1249-1258. [PMID: 33914041 PMCID: PMC8135537 DOI: 10.1093/clinchem/hvab069] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 04/13/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND Low initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers dropping to undetectable levels within months after infection have raised concerns about long-term immunity. Both the antibody levels and the avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response. METHODS A testing-on-a-probe "plus" panel (TOP-Plus) was developed to include a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM, and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months after infection in paired samples from 80 patients with coronavirus disease 2019 (COVID-19). Sera from individuals vaccinated for SARS-CoV-2 were also evaluated for antibody avidity. RESULTS The newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (r = 0.88). The imprecision of the TOP avidity assay was <10%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months after infection, the antibody avidity increased significantly (P < 0.0001). Antibody avidity in 10 SARS-CoV-2 vaccinated individuals (median: 28 days after vaccination) was comparable to the measured antibody avidity in infected individuals (median: 26 days after infection). CONCLUSIONS This highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG, and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only patients infected with SARS-CoV-2 but also the status of individuals' COVID-19 vaccination response.
Collapse
Affiliation(s)
- Sabrina E Racine-Brzostek
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| | | | - Christian Gaebler
- Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA
| | - P J Klasse
- Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA
| | - Jim Yee
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| | - Marina Caskey
- Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA
| | - He S Yang
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| | - Ying Hao
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
| | - Ashley Sukhu
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Sophie Rand
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Amy Chadburn
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| | - Yuanyuan Shi
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
| | | | - Michel C Nussenzweig
- Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA
- Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | - Melissa M Cushing
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| | - Zhen Zhao
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA
| |
Collapse
|
16
|
Pradhan M, Shah K, Alexander A, Ajazuddin, Minz S, Singh MR, Singh D, Yadav K, Chauhan NS. COVID-19: clinical presentation and detection methods. J Immunoassay Immunochem 2021; 43:1951291. [PMID: 34355645 DOI: 10.1080/15321819.2021.1951291] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The unending outburst of COVID-19 has reinforced the necessity of SARS-CoV-2 identification approaches for the prevention of infection transmission and the proper care of severe and critical patients. As there is no cure, a prompt and reliable diagnosis of SARS-CoV2 is vital to counter the spread and to provide adequate care and treatment for the infection. Currently, RT-PCR is a gold standard detection method for the qualitative and quantitative detection of viral nucleic acids. Besides, enzyme-linked immunosorbent assay is also a primarily used method for qualitative estimation of viral load. However, almost all the detection methods have their pros and cons in terms of specificity, accuracy, sensitivity, cost, time consumption, the need for sophisticated laboratories, and the requirement of skilled technical experts to carry out the detection tests. Thus, it is suggested to integrate different techniques to enhance the detection efficiency and accurateness for SARS-CoV2. This review focuses on preliminary, pre-confirmatory, and confirmatory methods of detection such as imaging techniques (chest-X-ray and chest- computed tomography), nucleic acid detection methods, serological assay methods, and viral culture and identification methods that are currently being employed to detect the presence of SARS-CoV-2 infection along with recent detection method and applicability for COVID-19.
Collapse
Affiliation(s)
- Madhulika Pradhan
- Department of Pharmacy, Rungta College of Pharmaceutical Sciences and Research, Bhilai, India
| | - Kamal Shah
- Institute of Pharmaceutical Research,GLA University, Mathura, India
| | - Amit Alexander
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-G), Ministry of Chemicals and Fertilizers, Guwahati, India
| | - Ajazuddin
- Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM's NMIMS, Shirpur, 425405, Maharashtra, India
| | - Sunita Minz
- Department of Pharmacy, Indira Gandhi National Tribal University, annupur, India
| | - Manju Rawat Singh
- University Institute of Pharmacy, Pandit Ravishankar Shukla University Institute of Pharmacy, Raipur, India
| | - Deependra Singh
- University Institute of Pharmacy, Pandit Ravishankar Shukla University Institute of Pharmacy, Raipur, India
| | - Krishna Yadav
- University Institute of Pharmacy, Pandit Ravishankar Shukla University Institute of Pharmacy, Raipur, India
| | | |
Collapse
|
17
|
Hober S, Hellström C, Olofsson J, Andersson E, Bergström S, Jernbom Falk A, Bayati S, Mravinacova S, Sjöberg R, Yousef J, Skoglund L, Kanje S, Berling A, Svensson AS, Jensen G, Enstedt H, Afshari D, Xu LL, Zwahlen M, von Feilitzen K, Hanke L, Murrell B, McInerney G, Karlsson Hedestam GB, Lendel C, Roth RG, Skoog I, Svenungsson E, Olsson T, Fogdell-Hahn A, Lindroth Y, Lundgren M, Maleki KT, Lagerqvist N, Klingström J, Da Silva Rodrigues R, Muschiol S, Bogdanovic G, Arroyo Mühr LS, Eklund C, Lagheden C, Dillner J, Sivertsson Å, Havervall S, Thålin C, Tegel H, Pin E, Månberg A, Hedhammar M, Nilsson P. Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. Clin Transl Immunology 2021; 10:e1312. [PMID: 34295471 PMCID: PMC8288725 DOI: 10.1002/cti2.1312] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 06/20/2021] [Accepted: 06/22/2021] [Indexed: 12/14/2022] Open
Abstract
Objective The COVID-19 pandemic poses an immense need for accurate, sensitive and high-throughput clinical tests, and serological assays are needed for both overarching epidemiological studies and evaluating vaccines. Here, we present the development and validation of a high-throughput multiplex bead-based serological assay. Methods More than 100 representations of SARS-CoV-2 proteins were included for initial evaluation, including antigens produced in bacterial and mammalian hosts as well as synthetic peptides. The five best-performing antigens, three representing the spike glycoprotein and two representing the nucleocapsid protein, were further evaluated for detection of IgG antibodies in samples from 331 COVID-19 patients and convalescents, and in 2090 negative controls sampled before 2020. Results Three antigens were finally selected, represented by a soluble trimeric form and the S1-domain of the spike glycoprotein as well as by the C-terminal domain of the nucleocapsid. The sensitivity for these three antigens individually was found to be 99.7%, 99.1% and 99.7%, and the specificity was found to be 98.1%, 98.7% and 95.7%. The best assay performance was although achieved when utilising two antigens in combination, enabling a sensitivity of up to 99.7% combined with a specificity of 100%. Requiring any two of the three antigens resulted in a sensitivity of 99.7% and a specificity of 99.4%. Conclusion These observations demonstrate that a serological test based on a combination of several SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.
Collapse
|
18
|
Mavrikou S, Tsekouras V, Hatziagapiou K, Paradeisi F, Bakakos P, Michos A, Koutsoukou A, Konstantellou E, Lambrou GI, Koniari E, Tatsi EB, Papaparaskevas J, Iliopoulos D, Chrousos GP, Kintzios S. Clinical Application of the Novel Cell-Based Biosensor for the Ultra-Rapid Detection of the SARS-CoV-2 S1 Spike Protein Antigen: A Practical Approach. Biosensors (Basel) 2021; 11:224. [PMID: 34356695 DOI: 10.3390/bios11070224] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/01/2021] [Accepted: 07/03/2021] [Indexed: 12/13/2022]
Abstract
The availability of antigen tests for SARS-CoV-2 represents a major step for the mass surveillance of the incidence of infection, especially regarding COVID-19 asymptomatic and/or early-stage patients. Recently, we reported the development of a Bioelectric Recognition Assay-based biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus in just three minutes, with high sensitivity and selectivity. The working principle was established by measuring the change of the electric potential of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody after attachment of the respective viral protein. In the present study, we applied the novel biosensor to patient-derived nasopharyngeal samples in a clinical set-up, with absolutely no sample pretreatment. More importantly, membrane-engineered cells were pre-immobilized in a proprietary biomatrix, thus enabling their long-term preservation prior to use as well as significantly increasing their ease-of-handle as test consumables. The plug-and-apply novel biosensor was able to detect the virus in positive samples with a 92.8% success rate compared to RT-PCR. No false negative results were recorded. These findings demonstrate the potential applicability of the biosensor for the early, routine mass screening of SARS-CoV-2 on a scale not yet realized.
Collapse
|
19
|
Wagner TR, Ostertag E, Kaiser PD, Gramlich M, Ruetalo N, Junker D, Haering J, Traenkle B, Becker M, Dulovic A, Schweizer H, Nueske S, Scholz A, Zeck A, Schenke‐Layland K, Nelde A, Strengert M, Walz JS, Zocher G, Stehle T, Schindler M, Schneiderhan‐Marra N, Rothbauer U. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. EMBO Rep 2021; 22:e52325. [PMID: 33904225 PMCID: PMC8097376 DOI: 10.15252/embr.202052325] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 03/23/2021] [Accepted: 03/25/2021] [Indexed: 12/23/2022] Open
Abstract
In light of the COVID-19 pandemic, there is an ongoing need for diagnostic tools to monitor the immune status of large patient cohorts and the effectiveness of vaccination campaigns. Here, we present 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potently inhibit the interaction of RBD with angiotensin-converting enzyme 2 (ACE2) as the major viral docking site. Following detailed epitope mapping and structural analysis, we select two inhibitory Nbs, one of which binds an epitope inside and one of which binds an epitope outside the RBD:ACE2 interface. Based on these, we generate a biparatopic nanobody (bipNb) with viral neutralization efficacy in the picomolar range. Using bipNb as a surrogate, we establish a competitive multiplex binding assay ("NeutrobodyPlex") for detailed analysis of the presence and performance of neutralizing RBD-binding antibodies in serum of convalescent or vaccinated patients. We demonstrate that NeutrobodyPlex enables high-throughput screening and detailed analysis of neutralizing immune responses in infected or vaccinated individuals, to monitor immune status or to guide vaccine design.
Collapse
Affiliation(s)
- Teresa R Wagner
- Pharmaceutical BiotechnologyEberhard Karls UniversityTuebingenGermany
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Elena Ostertag
- Interfaculty Institute of BiochemistryEberhard Karls UniversityTuebingenGermany
| | - Philipp D Kaiser
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Marius Gramlich
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Natalia Ruetalo
- Institute for Medical Virology and Epidemiology of Viral DiseasesUniversity Hospital TuebingenTuebingenGermany
| | - Daniel Junker
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Julia Haering
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Bjoern Traenkle
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Matthias Becker
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Alex Dulovic
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Helen Schweizer
- Livestock Center of the Faculty of Veterinary MedicineLudwig Maximilians UniversityOberschleissheimGermany
| | - Stefan Nueske
- Livestock Center of the Faculty of Veterinary MedicineLudwig Maximilians UniversityOberschleissheimGermany
| | - Armin Scholz
- Livestock Center of the Faculty of Veterinary MedicineLudwig Maximilians UniversityOberschleissheimGermany
| | - Anne Zeck
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
| | - Katja Schenke‐Layland
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
- Cluster of Excellence iFIT (EXC2180) “Image‐Guided and Functionally Instructed Tumor Therapies”Eberhard Karls UniversityTuebingenGermany
- Department of Women’s HealthResearch Institute for Women’s HealthEberhard Karls UniversityTuebingenGermany
- Department of Medicine/CardiologyCardiovascular Research LaboratoriesDavid Geffen School of Medicine at UCLALos AngelesCAUSA
| | - Annika Nelde
- Cluster of Excellence iFIT (EXC2180) “Image‐Guided and Functionally Instructed Tumor Therapies”Eberhard Karls UniversityTuebingenGermany
- Clinical Collaboration Unit Translational ImmunologyGerman Cancer Consortium (DKTK)Department of Internal MedicineUniversity Hospital TuebingenTuebingenGermany
- Institute for Cell BiologyDepartment of ImmunologyEberhard Karls UniversityTuebingenGermany
| | - Monika Strengert
- Department of EpidemiologyHelmholtz Centre for Infection ResearchBraunschweigGermany
- TWINCORE GmbHCentre for Experimental and Clinical Infection ResearchA Joint venture of the Hannover Medical School and the Helmholtz Centre for Infection ResearchHannoverGermany
| | - Juliane S Walz
- Cluster of Excellence iFIT (EXC2180) “Image‐Guided and Functionally Instructed Tumor Therapies”Eberhard Karls UniversityTuebingenGermany
- Clinical Collaboration Unit Translational ImmunologyGerman Cancer Consortium (DKTK)Department of Internal MedicineUniversity Hospital TuebingenTuebingenGermany
- Institute for Cell BiologyDepartment of ImmunologyEberhard Karls UniversityTuebingenGermany
- Dr. Margarete Fischer‐Bosch Institute of Clinical Pharmacology and Robert Bosch Center for Tumor DiseaseRBCTStuttgartGermany
| | - Georg Zocher
- Interfaculty Institute of BiochemistryEberhard Karls UniversityTuebingenGermany
| | - Thilo Stehle
- Interfaculty Institute of BiochemistryEberhard Karls UniversityTuebingenGermany
- Vanderbilt University School of MedicineNashvilleTNUSA
| | - Michael Schindler
- Institute for Medical Virology and Epidemiology of Viral DiseasesUniversity Hospital TuebingenTuebingenGermany
| | | | - Ulrich Rothbauer
- Pharmaceutical BiotechnologyEberhard Karls UniversityTuebingenGermany
- Natural and Medical Sciences InstituteUniversity of TuebingenReutlingenGermany
- Cluster of Excellence iFIT (EXC2180) “Image‐Guided and Functionally Instructed Tumor Therapies”Eberhard Karls UniversityTuebingenGermany
| |
Collapse
|
20
|
Owers Bonner KA, Cruz JS, Sacramento GA, de Oliveira D, Nery N, Carvalho M, Costa F, Childs JE, Ko AI, Diggle PJ. Effects of Accounting for Interval-Censored Antibody Titer Decay on Seroincidence in a Longitudinal Cohort Study of Leptospirosis. Am J Epidemiol 2021; 190:893-899. [PMID: 33274738 DOI: 10.1093/aje/kwaa253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 11/14/2020] [Accepted: 11/16/2020] [Indexed: 12/23/2022] Open
Abstract
Accurate measurements of seroincidence are critical for infections undercounted by reported cases, such as influenza, arboviral diseases, and leptospirosis. However, conventional methods of interpreting paired serological samples do not account for antibody titer decay, resulting in underestimated seroincidence rates. To improve interpretation of paired sera, we modeled exponential decay of interval-censored microscopic agglutination test titers using a historical data set of leptospirosis cases traced to a point source exposure in Italy in 1984. We then applied that decay rate to a longitudinal cohort study conducted in a high-transmission setting in Salvador, Brazil (2013-2015). We estimated a decay constant of 0.926 (95% confidence interval: 0.918, 0.934) titer dilutions per month. Accounting for decay in the cohort increased the mean infection rate to 1.21 times the conventionally defined rate over 6-month intervals (range, 1.10-1.36) and 1.82 times that rate over 12-month intervals (range, 1.65-2.07). Improved estimates of infection in longitudinal data have broad epidemiologic implications, including comparing studies with different sampling intervals, improving sample size estimation, and determining risk factors for infection and the role of acquired immunity. Our method of estimating and accounting for titer decay is generalizable to other infections defined using interval-censored serological assays.
Collapse
|
21
|
Touloudi A, Valiakos G, Cawthraw S, Kostoulas P, Gortázar C, Boadella M, Giannakopoulos A, Birtsas P, Sofia M, Athanasiou LV, Satra M, Athanasakopoulou Z, Kantere M, Spyrou V, Petrovska L, Billinis C. Development of a Multiplex Bead Assay for Simultaneous Serodiagnosis of Antibodies against Mycobacterium bovis, Brucella suis, and Trichinella spiralis in Wild Boar. Microorganisms 2021; 9:microorganisms9050904. [PMID: 33922494 PMCID: PMC8144985 DOI: 10.3390/microorganisms9050904] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 04/16/2021] [Accepted: 04/20/2021] [Indexed: 11/16/2022] Open
Abstract
The aim of this study was to evaluate the diagnostic performance of a multiplex bead assay for the simultaneous detection of antibodies against Mycobacterium bovis, Brucella suis, and Trichinella spiralis. Sera from Eurasian wild boar of known serological status for TB (64 seropositive, 106 seronegative), Brucella (30 seropositive, 39 seronegative), and Trichinella (21 seropositive, 97 seronegative) were used for the development and evaluation of the assay. Magnetic beads coated with recombinant MPB83 antigen (TB), a whole-cell B. suis 1330 antigen, and an E/S T. spiralis antigen were used for the detection of specific antibodies using Bio-Rad Bio-Plex technology. The sensitivities (Se) and specificities (Sp) of the multiplex assay were, for M. bovis, 0.98 and 0.86; for B. suis, 1.00 and 0.97; and for T. spiralis, 0.90 and 0.99 (Se and Sp, respectively). The results show the diagnostic potential of this assay for the simultaneous detection of antibodies against M. bovis, B. suis, and T. spiralis in wild boar.
Collapse
Affiliation(s)
- Antonia Touloudi
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - George Valiakos
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Shaun Cawthraw
- Animal and Plant Health Agency, Addlestone KT15 3NB, UK; (S.C.); (L.P.)
| | - Polychronis Kostoulas
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
- Faculty of Public and Integrated Health, University of Thessaly, 431 00 Karditsa, Greece;
| | - Christian Gortázar
- SaBio, Instituto de Investigación en Recursos Cinegéticos IREC, 13005 Ciudad Real, Spain;
| | | | - Alexios Giannakopoulos
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Periklis Birtsas
- Faculty of Forestry, Wood Science and Design, 431 00 Karditsa, Greece;
| | - Marina Sofia
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Labrini V. Athanasiou
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Maria Satra
- Faculty of Public and Integrated Health, University of Thessaly, 431 00 Karditsa, Greece;
| | - Zoi Athanasakopoulou
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Maria Kantere
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
| | - Vassiliki Spyrou
- Faculty of Animal Science, University of Thessaly, 412 22 Larissa, Greece;
| | - Liljana Petrovska
- Animal and Plant Health Agency, Addlestone KT15 3NB, UK; (S.C.); (L.P.)
| | - Charalambos Billinis
- Faculty of Veterinary Science, University of Thessaly, 431 00 Karditsa, Greece; (A.T.); (G.V.); (P.K.); (A.G.); (M.S.); (L.V.A.); (Z.A.); (M.K.)
- Faculty of Public and Integrated Health, University of Thessaly, 431 00 Karditsa, Greece;
- Correspondence:
| |
Collapse
|
22
|
Azad T, Rezaei R, Singaravelu R, Jamieson TR, Crupi MJF, Surendran A, Poutou J, Taklifi P, Cowan J, Cameron DW, Ilkow CS. A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. Nanomaterials (Basel) 2021; 11:nano11030807. [PMID: 33809836 PMCID: PMC8004173 DOI: 10.3390/nano11030807] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 03/17/2021] [Accepted: 03/18/2021] [Indexed: 12/14/2022]
Abstract
High-throughput detection strategies for antibodies against SARS-CoV-2 in patients recovering from COVID-19, or in vaccinated individuals, are urgently required during this ongoing pandemic. Serological assays are the most widely used method to measure antibody responses in patients. However, most of the current methods lack the speed, stability, sensitivity, and specificity to be selected as a test for worldwide serosurveys. Here, we demonstrate a novel NanoBiT-based serological assay for fast and sensitive detection of SARS-CoV-2 RBD-specific antibodies in sera of COVID-19 patients. This assay can be done in high-throughput manner at 384 samples per hour and only requires a minimum of 5 μL of serum or 10 ng of antibody. The stability of our NanoBiT reporter in various temperatures (4–42 °C) and pH (4–12) settings suggests the assay will be able to withstand imperfect shipping and handling conditions for worldwide seroepidemiologic surveillance in the post-vaccination period of the pandemic. Our newly developed rapid assay is highly accessible and may facilitate a more cost-effective solution for seroconversion screening as vaccination efforts progress.
Collapse
Affiliation(s)
- Taha Azad
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Reza Rezaei
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Ragunath Singaravelu
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Taylor R. Jamieson
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Mathieu J. F. Crupi
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Abera Surendran
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Joanna Poutou
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
| | - Parisa Taklifi
- Department of Biotechnology, University of Tehran, Tehran 1417614411, Iran;
| | - Juthaporn Cowan
- Department of Medicine, Division of Infectious Disease, University of Ottawa at The Ottawa Hospital/Research Institute, Ottawa, ON K1H 8L6, Canada; (J.C.); (D.W.C.)
| | - Donald William Cameron
- Department of Medicine, Division of Infectious Disease, University of Ottawa at The Ottawa Hospital/Research Institute, Ottawa, ON K1H 8L6, Canada; (J.C.); (D.W.C.)
| | - Carolina S. Ilkow
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (T.A.); (R.R.); (R.S.); (T.R.J.); (M.J.F.C.); (A.S.); (J.P.)
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- Correspondence: ; Tel.: +1-613-737-8899 (ext. 75208)
| |
Collapse
|
23
|
Tuells J, Egoavil CM, Pena Pardo MA, Montagud AC, Montagud E, Caballero P, Zapater P, Puig-Barberá J, Hurtado-Sanchez JA. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). Int J Environ Res Public Health 2021; 18:ijerph18041908. [PMID: 33669412 PMCID: PMC7920410 DOI: 10.3390/ijerph18041908] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 02/06/2021] [Accepted: 02/09/2021] [Indexed: 12/24/2022]
Abstract
The implementation of strategies to mitigate possible cases of COVID-19 were addressed at the University of Alicante for the safe reopening of the 2020/2021 academic year. To discover the prevalence of immunity against SARS-CoV-2, a study was designed using a rapid immunoassay test (carried out between 6 and 22 July 2020), and in addition a cross-sectional survey was conducted on risk factors, symptoms, predisposition for becoming vaccinated, and sources of information about COVID-19. A random sample, stratified by students, faculty, and administrative staff, was selected. The seroprevalence found was 2.64% (39/1479; 95% CI 1.8–3.4), and the adjusted seroprevalence was 2.89% (95% CI 2.1–3.7). The average age of the students was 23.2 years old, and 47.6 years old for staff. In relation to COVID-19, the following was found: 17.7% pauci-symptomatic, 1.3% symptomatic, 5.5% contact with cases, 4.9% confined, and 0.3% PCR positive. More than 90% complied with preventive measures. The proportion willing to receive the COVID-19 vaccine was 91%. Their sources of information were the Internet (74%) and television (70.1%). They requested that the university offer information (45.1%), training (27%), and provide Personal Protective Equipment (PPE) (26.3%). Lastly, 87.9% would repeat the test. A plan was established that included the follow-up of cases and contacts, random sample testing, training courses, bimodal teaching, a specific website, and the distribution of PPE.
Collapse
Affiliation(s)
- Jose Tuells
- Department of Community Nursing, Preventive Medicine, Public Health and History of Science, University of Alicante, 03690 Alicante, Spain
- Correspondence: (J.T.); (C.M.E.); (P.C.)
| | - Cecilia M. Egoavil
- Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain; (M.A.P.P.); (P.Z.)
- Correspondence: (J.T.); (C.M.E.); (P.C.)
| | - María Angeles Pena Pardo
- Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain; (M.A.P.P.); (P.Z.)
| | - Ana C. Montagud
- Immunology Department, Fundación Jiménez Díaz University Hospital, 28040 Madrid, Spain;
| | - Emilia Montagud
- Primary Care Pharmacy Service, University Hospital of Torrevieja, 03186 Torrevieja, Alicante, Spain;
| | - Pablo Caballero
- Department of Community Nursing, Preventive Medicine, Public Health and History of Science, University of Alicante, 03690 Alicante, Spain
- Correspondence: (J.T.); (C.M.E.); (P.C.)
| | - Pedro Zapater
- Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain; (M.A.P.P.); (P.Z.)
| | | | | |
Collapse
|
24
|
Djukic T, Mladenovic M, Stanic-Vucinic D, Radosavljevic J, Smiljanic K, Sabljic L, Devic M, Cujic D, Vasovic T, Simovic A, Radomirovic M, Cirkovic Velickovic T. Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2. Virology 2021; 557:15-22. [PMID: 33582454 PMCID: PMC7871913 DOI: 10.1016/j.virol.2021.01.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 01/11/2021] [Indexed: 01/18/2023]
Abstract
Serological testing is important method for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nucleocapsid (N) protein is the most abundant virus derived protein and strong immunogen. We aimed to find its efficient, low-cost production. SARS-CoV-2 recombinant fragment of nucleocapsid protein (rfNP; 58-419 aa) was expressed in E. coli in soluble form, purified and characterized biochemically and immunologically. Purified rfNP has secondary structure of full-length recombinant N protein, with high percentage of disordered structure (34.2%) and of β-sheet (40.7%). rfNP was tested in immunoblot using sera of COVID-19 convalescent patients. ELISA was optimized with sera of RT-PCR confirmed positive symptomatic patients and healthy individuals. IgG detection sensitivity was 96% (47/50) and specificity 97% (67/68), while IgM detection was slightly lower (94% and 96.5%, respectively). Cost-effective approach for soluble recombinant N protein fragment production was developed, with reliable IgG and IgM antibodies detection of SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Teodora Djukic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Maja Mladenovic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Dragana Stanic-Vucinic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Jelena Radosavljevic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Katarina Smiljanic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Ljiljana Sabljic
- University of Belgrade, Institute for the Application of Nuclear Energy - INEP, Belgrade, Serbia
| | - Marija Devic
- University of Belgrade, Institute for the Application of Nuclear Energy - INEP, Belgrade, Serbia
| | - Danica Cujic
- University of Belgrade, Institute for the Application of Nuclear Energy - INEP, Belgrade, Serbia
| | - Tamara Vasovic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Ana Simovic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Mirjana Radomirovic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia
| | - Tanja Cirkovic Velickovic
- University of Belgrade-Faculty of Chemistry, Department of Biochemistry, Centre of Excellence for Molecular Food Sciences, Belgrade, Serbia; Ghent University Global Campus, Incheon, South Korea; Ghent University, Faculty of Bioscience Engineering, Ghent, Belgium; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
| |
Collapse
|
25
|
Zhang X, Li G, Chen G, Zhu N, Wu D, Wu Y, James TD. Recent progresses and remaining challenges for the detection of Zika virus. Med Res Rev 2021; 41:2039-2108. [PMID: 33559917 DOI: 10.1002/med.21786] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 12/23/2020] [Accepted: 01/05/2021] [Indexed: 12/26/2022]
Abstract
Zika virus (ZIKV) has emerged as a particularly notorious mosquito-borne flavivirus, which can lead to a devastating congenital syndrome in the fetuses of pregnant mothers (e.g., microcephaly, spasticity, craniofacial disproportion, miscarriage, and ocular abnormalities) and cause the autoimmune disorder Guillain-Barre' syndrome of adults. Due to its severity and rapid dispersal over several continents, ZIKV has been acknowledged to be a global health concern by the World Health Organization. Unfortunately, the ZIKV has recently resurged in India with the potential for devastating effects. Researchers from all around the world have worked tirelessly to develop effective detection strategies and vaccines for the prevention and control of ZIKV infection. In this review, we comprehensively summarize the most recent research into ZIKV, including the structural biology and evolution, historical overview, pathogenesis, symptoms, and transmission. We then focus on the detection strategies for ZIKV, including viral isolation, serological assays, molecular assays, sensing methods, reverse transcription loop mediated isothermal amplification, transcription-mediated amplification technology, reverse transcription strand invasion based amplification, bioplasmonic paper-based device, and reverse transcription isothermal recombinase polymerase amplification. To conclude, we examine the limitations of currently available strategies for the detection of ZIKV, and outline future opportunities and research challenges.
Collapse
Affiliation(s)
- Xianlong Zhang
- School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, China
| | - Guoliang Li
- School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, China
| | - Guang Chen
- School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an, China
| | - Niu Zhu
- Department of Public Health, Xi'an Medical University, Xi'an, China
| | - Di Wu
- Institute for Global Food Security, Queen's University Belfast, Belfast, UK
| | - Yongning Wu
- NHC Key Laboratory of Food Safety Risk Assessment, Food Safety Research Unit (2019RU014) of Chinese Academy of Medical Science, China National Center for Food Safety Risk Assessment, Beijing, China
| | - Tony D James
- Department of Chemistry, University of Bath, Bath, UK.,School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China
| |
Collapse
|
26
|
Shkilna M, Andreychyn M, Korda M, Pokryshko O, Humenna R, Huk M, Liu S, Rogovskyy AS. Serological Surveillance of Hospitalized Patients for Lyme Borreliosis in Ukraine. Vector Borne Zoonotic Dis 2021; 21:301-303. [PMID: 33688747 PMCID: PMC7997712 DOI: 10.1089/vbz.2020.2715] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Objectives: Although in Ukraine the incidence of Lyme borreliosis (LB) has been surging up over the past decades, seroepidemiologic data are not available to date. The objective of this report was to perform preliminary serological survey of hospitalized population for LB. Methods: Sera were collected from 203 patients of a hospital located in Western Ukraine. Most patients showed clinical signs that were compatible with LB such as arthritis (n = 29), neurological signs (n = 35), and erythema migrans (EM)-like lesions (n = 60) or unrelated to LB (n = 79). The specimens were tested by enzyme-linked immunosorbent assay and Western blot for anti-Borrelia antibodies. Results: LB was confirmed in 8.6%, 34.5%, and 50% of the patients, who exhibited neurological signs, arthritis, or EM-like lesions, respectively. Anti-Borrelia antibodies were also detected in 6.3% of the patients with pulmonary tuberculosis. Conclusions: This study provides the first preliminary data on the seroprevalence of LB in Ukraine. Future studies are warranted to investigate more subsets of the Ukrainian population for this emerging tick-borne disease.
Collapse
Affiliation(s)
- Mariia Shkilna
- Department of Infectious Diseases and Epidemiology, Dermatology and Venereology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Mykhailo Andreychyn
- Department of Infectious Diseases and Epidemiology, Dermatology and Venereology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Mykhailo Korda
- Department of Medical Biochemistry, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Olena Pokryshko
- Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Roksolana Humenna
- Department of Infectious Diseases and Epidemiology, Dermatology and Venereology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Mariana Huk
- Department of Infectious Diseases and Epidemiology, Dermatology and Venereology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Shuling Liu
- Statistical Collaboration Center, Department of Statistics, College of Science, Texas A&M University, College Station, Texas, USA
| | - Artem S Rogovskyy
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA
| |
Collapse
|
27
|
Johari YB, Jaffé SRP, Scarrott JM, Johnson AO, Mozzanino T, Pohle TH, Maisuria S, Bhayat-Cammack A, Lambiase G, Brown AJ, Tee KL, Jackson PJ, Wong TS, Dickman MJ, Sargur RB, James DC. Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnol Bioeng 2021; 118:1013-1021. [PMID: 33128388 DOI: 10.1002/bit.27615] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 10/14/2020] [Accepted: 10/27/2020] [Indexed: 12/27/2022]
Abstract
We describe scalable and cost-efficient production of full length, His-tagged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein trimer by Chinese hamster ovary (CHO) cells that can be used to detect SARS-CoV-2 antibodies in patient sera at high specificity and sensitivity. Transient production of spike in both human embryonic kidney (HEK) and CHO cells mediated by polyethyleneimine was increased significantly (up to 10.9-fold) by a reduction in culture temperature to 32°C to permit extended duration cultures. Based on these data GS-CHO pools stably producing spike trimer under the control of a strong synthetic promoter were cultured in hypothermic conditions with combinations of bioactive small molecules to increase yield of purified spike product 4.9-fold to 53 mg/L. Purification of recombinant spike by Ni-chelate affinity chromatography initially yielded a variety of co-eluting protein impurities identified as host cell derived by mass spectrometry, which were separated from spike trimer using a modified imidazole gradient elution. Purified CHO spike trimer antigen was used in enzyme-linked immunosorbent assay format to detect immunoglobulin G antibodies against SARS-CoV-2 in sera from patient cohorts previously tested for viral infection by polymerase chain reaction, including those who had displayed coronavirus disease 2019 (COVID-19) symptoms. The antibody assay, validated to ISO 15189 Medical Laboratories standards, exhibited a specificity of 100% and sensitivity of 92.3%. Our data show that CHO cells are a suitable host for the production of larger quantities of recombinant SARS-CoV-2 trimer which can be used as antigen for mass serological testing.
Collapse
Affiliation(s)
- Yusuf B Johari
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Stephen R P Jaffé
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Joseph M Scarrott
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Abayomi O Johnson
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Théo Mozzanino
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Thilo H Pohle
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Sheetal Maisuria
- Department of Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Amina Bhayat-Cammack
- Department of Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Giulia Lambiase
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Adam J Brown
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Kang Lan Tee
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Philip J Jackson
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Tuck Seng Wong
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Mark J Dickman
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| | - Ravishankar B Sargur
- Department of Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - David C James
- Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK
| |
Collapse
|
28
|
Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, Rouphael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. ACTA ACUST UNITED AC 2020; 131:e116. [PMID: 33215858 DOI: 10.1002/cpim.116] [Citation(s) in RCA: 86] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
SARS-CoV-2 is a recently emerged human coronavirus that has escalated to a pandemic. There are currently no approved vaccines for SARS-CoV-2, which causes severe respiratory illness or death. Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Here we describe two methods for evaluating the neutralization capacity of SARS-CoV-2 antibodies. The basic protocol is a focus reduction neutralization test (FRNT), which involves immunostaining infected cells with a chromogen deposit readout. The alternate protocol is a modification of the FRNT that uses an infectious clone-derived SARS-CoV-2 virus expressing a fluorescent reporter. These protocols are adapted for use in a high-throughput setting, and are compatible with large-scale vaccine studies or clinical testing. © 2020 Wiley Periodicals LLC Basic Protocol: Focus reduction neutralization test Alternate Protocol: mNeonGreen-based focus reduction neutralization test (FRNT-mNG).
Collapse
Affiliation(s)
- Abigail Vanderheiden
- Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia.,Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Yerkes National Primate Research Center, Atlanta, Georgia
| | - Venkata Viswanadh Edara
- Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia.,Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Yerkes National Primate Research Center, Atlanta, Georgia
| | - Katharine Floyd
- Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia.,Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Yerkes National Primate Research Center, Atlanta, Georgia
| | - Robert C Kauffman
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia
| | - Grace Mantus
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia
| | - Evan Anderson
- Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia
| | - Nadine Rouphael
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Department of Medicine, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia
| | - Sri Edupuganti
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Department of Medicine, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia
| | - Pei-Yong Shi
- Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas
| | - Vineet D Menachery
- Department of Microbiology and Immunology, Institute for Human Infection and Immunity, World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas
| | - Jens Wrammert
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia
| | - Mehul S Suthar
- Department of Pediatrics, Division of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia.,Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.,Yerkes National Primate Research Center, Atlanta, Georgia
| |
Collapse
|
29
|
Almahboub SA, Algaissi A, Alfaleh MA, ElAssouli MZ, Hashem AM. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. Front Microbiol 2020; 11:2020. [PMID: 33013745 PMCID: PMC7498578 DOI: 10.3389/fmicb.2020.02020] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 07/30/2020] [Indexed: 12/13/2022] Open
Abstract
Emerging highly pathogenic human coronaviruses (CoVs) represent a serious ongoing threat to the public health worldwide. The spike (S) proteins of CoVs are surface glycoproteins that facilitate viral entry into host cells via attachment to their respective cellular receptors. The S protein is believed to be a major immunogenic component of CoVs and a target for neutralizing antibodies (nAbs) and most candidate vaccines. Development of a safe and convenient assay is thus urgently needed to determine the prevalence of CoVs nAbs in the population, to study immune response in infected individuals, and to aid in vaccines and viral entry inhibitor evaluation. While live virus-based neutralization assays are used as gold standard serological methods to detect and measure nAbs, handling of highly pathogenic live CoVs requires strict bio-containment conditions in biosafety level-3 (BSL-3) laboratories. On the other hand, use of replication-incompetent pseudoviruses bearing CoVs S proteins could represent a safe and useful method to detect nAbs in serum samples under biosafety level-2 (BSL-2) conditions. Here, we describe a detailed protocol of a safe and convenient assay to generate vesicular stomatitis virus (VSV)-based pseudoviruses to evaluate and measure nAbs against highly pathogenic CoVs. The protocol covers methods to produce VSV pseudovirus bearing the S protein of the Middle East respiratory syndrome-CoV (MERS-CoV) and the severe acute respiratory syndrome-CoV-2 (SARS-CoV-2), pseudovirus titration, and pseudovirus neutralization assay. Such assay could be adapted by different laboratories and researchers working on highly pathogenic CoVs without the need to handle live viruses in the BSL-3 environment.
Collapse
Affiliation(s)
- Sarah A. Almahboub
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Abdullah Algaissi
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
- Medical Research Center, Jazan University, Jazan, Saudi Arabia
| | - Mohamed A. Alfaleh
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
- Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - M-Zaki ElAssouli
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Anwar M. Hashem
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
- Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
30
|
Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 2020; 57:e100. [PMID: 32302069 PMCID: PMC7235504 DOI: 10.1002/cpmc.100] [Citation(s) in RCA: 510] [Impact Index Per Article: 127.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was quickly identified as a betacoronavirus (named SARS-CoV-2), which has since caused a pandemic. Several methods allowing for the specific detection of viral nucleic acids have been established, but these only allow detection of the virus during a short period of time, generally during acute infection. Serological assays are urgently needed to conduct serosurveys, to understand the antibody responses mounted in response to the virus, and to identify individuals who are potentially immune to re-infection. Here we describe a detailed protocol for expression of antigens derived from the spike protein of SARS-CoV-2 that can serve as a substrate for immunological assays, as well as a two-stage serological enzyme-linked immunosorbent assay (ELISA). These assays can be used for research studies and for testing in clinical laboratories. © 2020 The Authors. Basic Protocol 1: Mammalian cell transfection and protein purification Basic Protocol 2: A two-stage ELISA for high-throughput screening of human serum samples for antibodies binding to the spike protein of SARS-CoV-2.
Collapse
MESH Headings
- Antibodies, Viral/blood
- Antigens, Viral/biosynthesis
- Antigens, Viral/isolation & purification
- Betacoronavirus/immunology
- COVID-19
- COVID-19 Testing
- Clinical Laboratory Techniques/methods
- Coronavirus Infections/blood
- Coronavirus Infections/diagnosis
- Coronavirus Infections/immunology
- HEK293 Cells
- Humans
- Pandemics
- Pneumonia, Viral/blood
- Pneumonia, Viral/diagnosis
- Pneumonia, Viral/immunology
- Recombinant Proteins/immunology
- Recombinant Proteins/isolation & purification
- SARS-CoV-2
- Seroconversion
- Spike Glycoprotein, Coronavirus/biosynthesis
- Spike Glycoprotein, Coronavirus/genetics
- Spike Glycoprotein, Coronavirus/immunology
- Spike Glycoprotein, Coronavirus/isolation & purification
Collapse
Affiliation(s)
- Daniel Stadlbauer
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Fatima Amanat
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Graduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Veronika Chromikova
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Kaijun Jiang
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Shirin Strohmeier
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Department of BiotechnologyUniversity of Natural Resources and Life SciencesViennaAustria
| | - Guha Asthagiri Arunkumar
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Graduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Jessica Tan
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Graduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Disha Bhavsar
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Christina Capuano
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Ericka Kirkpatrick
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Graduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Philip Meade
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Graduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Ruhi Nichalle Brito
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Catherine Teo
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Meagan McMahon
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Viviana Simon
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
- Global Health Emerging Pathogens InstituteIcahn School of Medicine at Mount SinaiNew York
- Division of Infectious Diseases, Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkNew York
| | - Florian Krammer
- Department of MicrobiologyIcahn School of Medicine at Mount SinaiNew YorkNew York
| |
Collapse
|
31
|
Mavrikou S, Moschopoulou G, Tsekouras V, Kintzios S. Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen. Sensors (Basel) 2020; 20:s20113121. [PMID: 32486477 PMCID: PMC7309076 DOI: 10.3390/s20113121] [Citation(s) in RCA: 151] [Impact Index Per Article: 37.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 05/18/2020] [Accepted: 05/29/2020] [Indexed: 12/14/2022]
Abstract
One of the key challenges of the recent COVID-19 pandemic is the ability to accurately estimate the number of infected individuals, particularly asymptomatic and/or early-stage patients. We herewith report the proof-of-concept development of a biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus. The biosensor is based on membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody. We demonstrate that the attachment of the protein to the membrane-bound antibodies resulted in a selective and considerable change in the cellular bioelectric properties measured by means of a Bioelectric Recognition Assay. The novel biosensor provided results in an ultra-rapid manner (3 min), with a detection limit of 1 fg/mL and a semi-linear range of response between 10 fg and 1 μg/mL. In addition, no cross-reactivity was observed against the SARS-CoV-2 nucleocapsid protein. Furthermore, the biosensor was configured as a ready-to-use platform, including a portable read-out device operated via smartphone/tablet. In this way, we demonstrate that the novel biosensor can be potentially applied for the mass screening of SARS-CoV-2 surface antigens without prior sample processing, therefore offering a possible solution for the timely monitoring and eventual control of the global coronavirus pandemic.
Collapse
|
32
|
He B, Zhang Z, Zhang X, Tang Z, Liu C, Zheng Z, Li S, Zhang J, Xia N, Zhao Q. Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent. Hum Vaccin Immunother 2020; 16:1554-1564. [PMID: 31995442 DOI: 10.1080/21645515.2019.1703454] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Hepatitis E virus (HEV) is responsible for epidemic and sporadic acute hepatitis cases, especially in developing countries. Hepatitis E has become a vaccine-preventable disease in recent years with the development of a licensed vaccine. Most functional and neutralizing monoclonal antibodies (mAbs) are known to be highly sensitive to antigen conformation. In this study, a similar approach was used to characterize the conformational sensitivity of antibodies in human or mouse serum samples. Interestingly, comparative binding analysis using different antigen forms showed that the antibodies in the sera of naturally infected individuals, of human vaccinees and from mice immunized with the HEV p239 vaccine all exhibited a strong preference to particulate antigens over the monomeric form of the truncated capsid protein. The degree of discriminating the two test antigens is similar for serum samples to that for the well-characterized murine mAbs. A functional assay for assessing the inhibition of subviral particle cell entry by antibodies was used to determine the functional titers of anti-HEV antibodies in mouse sera. A good correlation was observed between the functional and binding titers in mouse sera determined using two different methods. This result supports the continued use of the enzyme-linked immunosorbent assay as the primary serological assay assuming that the coating antigen contains conformational and native-like epitopes, as in the case for HEV p239.
Collapse
Affiliation(s)
- Bin He
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Zhigang Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Xinyuan Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Zimin Tang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Chang Liu
- School of Life Science, Xiamen University , Xiamen, Fujian, PR China
| | - Zizheng Zheng
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Shaowei Li
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China.,School of Life Science, Xiamen University , Xiamen, Fujian, PR China
| | - Jun Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| | - Ningshao Xia
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China.,School of Life Science, Xiamen University , Xiamen, Fujian, PR China
| | - Qinjian Zhao
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University , Xiamen, Fujian, PR China
| |
Collapse
|
33
|
Dupke S, Barduhn A, Franz T, Leendertz FH, Couacy-Hymann E, Grunow R, Klee SR. Analysis of a newly discovered antigen of Bacillus cereus biovar anthracis for its suitability in specific serological antibody testing. J Appl Microbiol 2018; 126:311-323. [PMID: 30253024 DOI: 10.1111/jam.14114] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 08/31/2018] [Accepted: 09/12/2018] [Indexed: 12/21/2022]
Abstract
AIMS The aim of this work was to identify a protein which can be used for specific detection of antibodies against Bacillus cereus biovar anthracis (Bcbva), an anthrax-causing pathogen that so far has been described in African rainforest areas. METHODS AND RESULTS Culture supernatants of Bcbva and classic Bacillus anthracis (Ba) were analysed by gel electrophoresis, and a 35-kDa protein secreted only by Bcbva and not Ba was detected. The protein was identified as pXO2-60 by mass spectrometry. Sequence analysis showed that Ba is unable to secrete this protein due to a premature stop codon in the sequence for the signal peptide. Immunization of five outbred mice with sterile bacterial culture supernatants of Bcbva revealed an immune response in ELISA against pXO2-60 (three mice positive, one borderline) and the protective antigen (PA; four mice). When supernatants of classic Ba were injected into mice or human sera from anthrax patients were analysed, only antibodies against PA were detected. CONCLUSIONS In combination with PA, the pXO2-60 protein can be used for the detection of antibodies specific against Bcbva and discriminating from Ba. SIGNIFICANCE AND IMPACT OF THE STUDY After further validation, serological assays based on pXO2-60 can be used to perform seroprevalence studies to determine the epidemiology of B. cereus bv anthracis in affected countries and assess its impact on the human population.
Collapse
Affiliation(s)
- S Dupke
- Robert Koch-Institute, Centre for Biological Threats and Special Pathogens (ZBS2), Berlin, Germany
| | - A Barduhn
- Robert Koch-Institute, Centre for Biological Threats and Special Pathogens (ZBS2), Berlin, Germany
| | - T Franz
- Robert Koch-Institute, Centre for Biological Threats and Special Pathogens (ZBS2), Berlin, Germany
| | - F H Leendertz
- Robert Koch-Institute, Epidemiology of Highly Pathogenic Microorganisms (P3), Berlin, Germany
| | - E Couacy-Hymann
- Laboratoire National d'Appui au Développement Agricole (LANADA), Laboratoire Central Vétérinaire de Bingerville (LCVB), Bingerville, Côte d'Ivoire
| | - R Grunow
- Robert Koch-Institute, Centre for Biological Threats and Special Pathogens (ZBS2), Berlin, Germany
| | - S R Klee
- Robert Koch-Institute, Centre for Biological Threats and Special Pathogens (ZBS2), Berlin, Germany
| |
Collapse
|
34
|
Roos EO, Olea-Popelka F, Buss P, de Klerk-Lorist LM, Cooper D, van Helden PD, Parsons SDC, Miller MA. Seroprevalence of Mycobacterium bovis infection in warthogs (Phacochoerus africanus) in bovine tuberculosis-endemic regions of South Africa. Transbound Emerg Dis 2018. [PMID: 29520985 DOI: 10.1111/tbed.12856] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Bovine tuberculosis (bTB), caused by Mycobacterium bovis (M. bovis), has been reported in many species including suids. Wild boar are important maintenance hosts of the infection with other suids, that is domestic and feral pigs, being important spillover hosts in the Eurasian ecosystem and in South Africa, warthogs (Phacochoerus africanus) may play a similar role in M. bovis-endemic areas. However, novel diagnostic tests for warthogs are required to investigate the epidemiology of bTB in this species. Recent studies have demonstrated that serological assays are capable of discriminating between M. bovis-infected and uninfected warthogs (Roos et al., ). In this study, an indirect ELISA utilizing M. bovis purified protein derivative (PPD) as a test antigen was used to measure the prevalence and investigate risk factors associated with infection in warthogs from uMhkuze Nature Reserve and the southern region of the Greater Kruger National Park (GKNP). There was a high overall seroprevalence of 38%, with adult warthogs having a higher risk of infection (46%). Seroprevalence also varied by geographic location with warthogs from Marloth Park in the GKNP having the greatest percentage of positive animals (63%). This study indicates that warthogs in M. bovis-endemic areas are at high risk of becoming infected with mycobacteria. Warthogs might present an under-recognized disease threat in multi-species systems. They might also serve as convenient sentinels for M. bovis in endemic areas. These findings highlight the importance of epidemiological studies in wildlife to understand the role each species plays in disease ecology.
Collapse
Affiliation(s)
- E O Roos
- Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - F Olea-Popelka
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - P Buss
- Veterinary Wildlife Services, South African National Parks, Kruger National Park, Skukuza, South Africa
| | - L-M de Klerk-Lorist
- Office of the State Veterinarian, Kruger National Park, Department of Agriculture, Forestry and Fisheries, Skukuza, South Africa
| | - D Cooper
- Ezemvelo KZN Wildlife, Mtubatuba, South Africa
| | - P D van Helden
- Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - S D C Parsons
- Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - M A Miller
- Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| |
Collapse
|
35
|
Balmaseda A, Zambrana JV, Collado D, García N, Saborío S, Elizondo D, Mercado JC, Gonzalez K, Cerpas C, Nuñez A, Corti D, Waggoner JJ, Kuan G, Burger-Calderon R, Harris E. Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. J Clin Microbiol 2018; 56:e01785-17. [PMID: 29305550 PMCID: PMC5824050 DOI: 10.1128/jcm.01785-17] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 12/22/2017] [Indexed: 11/20/2022] Open
Abstract
Zika virus (ZIKV) is a mosquito-borne flavivirus that is responsible for recent explosive epidemics in the Americas. Notably, ZIKV infection during pregnancy has been found to cause congenital birth defects, including microcephaly, and ZIKV has been associated with Guillain-Barré syndrome in adults. Diagnosis and surveillance of Zika in the Americas have been challenging due to similar clinical manifestations and extensive antibody cross-reactivity with endemic flaviviral diseases, such as dengue. We evaluated four serological and two reverse transcription-PCR (RT-PCR) methods in acute-phase (mean day, 1.8), early-convalescent-phase (mean day, 16.7), and late-convalescent-phase (mean, ~7 months) samples from the same individuals in a long-term pediatric cohort study in Nicaragua. Well-characterized samples from 301 cases of Zika, dengue, or non-Zika, nondengue febrile illnesses were tested. Compared to a composite reference, an in-house IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) and the NIAID-Biodefense and Emerging Infections (BEI) MAC-ELISA measuring IgM yielded sensitivities of 94.5% and 70.1% and specificities of 85.6% and 82.8%, respectively. The NS1 blockade-of-binding ELISA measuring anti-ZIKV NS1 antibody levels yielded sensitivities of 85.0% and 96.5% and specificities of 91.4% and 92.6% at early and late convalescence, respectively. An inhibition ELISA detecting total anti-ZIKV antibodies had sensitivity and specificity values of 68.3% and 58.3% for diagnosis and 94.0% and 98.6% for measuring annual infection incidence. Finally, the ZCD and Trioplex real-time RT-PCR assays detecting Zika, chikungunya, and dengue viruses both yielded a sensitivity of 96.1% and specificity of 100%. Together, these assays resolve the urgent need for diagnostic and surveillance tools for countries affected by Zika virus infections.
Collapse
Affiliation(s)
- Angel Balmaseda
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | | | | | - Nadezna García
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | - Saira Saborío
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | | | - Juan Carlos Mercado
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | - Karla Gonzalez
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | - Cristhiam Cerpas
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | - Andrea Nuñez
- Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua
- Sustainable Sciences Institute, Managua, Nicaragua
| | - Davide Corti
- Humabs Biomed SA, subsidiary of Vir Biotechnology, Inc., Bellinzona, Switzerland
| | - Jesse J Waggoner
- Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA
| | - Guillermina Kuan
- Sustainable Sciences Institute, Managua, Nicaragua
- Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua
| | - Raquel Burger-Calderon
- Sustainable Sciences Institute, Managua, Nicaragua
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA
| | - Eva Harris
- Sustainable Sciences Institute, Managua, Nicaragua
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA
| |
Collapse
|
36
|
Martin BE, Bowman AS, Li L, Nolting JM, Smith DR, Hanson LA, Wan XF. Detection of Antigenic Variants of Subtype H3 Swine Influenza A Viruses from Clinical Samples. J Clin Microbiol 2017; 55:1037-45. [PMID: 28077698 DOI: 10.1128/JCM.02049-16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 01/06/2017] [Indexed: 11/20/2022] Open
Abstract
A large population of genetically and antigenically diverse influenza A viruses (IAVs) are circulating among the swine population, playing an important role in influenza ecology. Swine IAVs not only cause outbreaks among swine but also can be transmitted to humans, causing sporadic infections and even pandemic outbreaks. Antigenic characterizations of swine IAVs are key to understanding the natural history of these viruses in swine and to selecting strains for effective vaccines. However, influenza outbreaks generally spread rapidly among swine, and the conventional methods for antigenic characterization require virus propagation, a time-consuming process that can significantly reduce the effectiveness of vaccination programs. We developed and validated a rapid, sensitive, and robust method, the polyclonal serum-based proximity ligation assay (polyPLA), to identify antigenic variants of subtype H3N2 swine IAVs. This method utilizes oligonucleotide-conjugated polyclonal antibodies and quantifies antibody-antigen binding affinities by quantitative reverse transcription-PCR (RT-PCR). Results showed the assay can rapidly detect H3N2 IAVs directly from nasal wash or nasal swab samples collected from laboratory-challenged animals or during influenza surveillance at county fairs. In addition, polyPLA can accurately separate the viruses at two contemporary swine IAV antigenic clusters (H3N2 swine IAV-α and H3N2 swine IAV-ß) with a sensitivity of 84.9% and a specificity of 100.0%. The polyPLA can be routinely used in surveillance programs to detect antigenic variants of influenza viruses and to select vaccine strains for use in controlling and preventing disease in swine.
Collapse
|
37
|
Yokota H, Nagaoka T, Sato E, Takahashi A, Shimouchi A, Yoshida A. Serum prorenin levels are not associated with ocular diseases in non-diabetic subjects. J Renin Angiotensin Aldosterone Syst 2014; 16:153-8. [PMID: 25324425 DOI: 10.1177/1470320314551442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Accepted: 08/12/2014] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION To determine if the serum prorenin level is useful for detecting ocular disease in a non-diabetic population. MATERIALS AND METHODS We enrolled non-diabetic men (n = 402) and women (n = 349) in our study. We used the antibody-activating direct enzyme kinetic assay of human prorenin to determine serum prorenin levels. We performed multiple regression analysis to determine the factors that affect serum prorenin levels, such as: age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, fasting blood sugar, and HbA1c or estimated glomerular filtration rate. Our study subjects were divided into groups by their ophthalmologic diagnosis. One-way analysis of variance (ANOVA) was performed to detect a significant difference in the serum prorenin levels among the groups. RESULTS There were no significant differences in serum prorenin levels among the ocular diseases and disorders. The DBP was negatively correlated with serum prorenin levels in men (r = - 0.1992; p = 0.021) and in women (r = - 0.2067; p = 0.031). CONCLUSION Considering the current results and those of previous studies together, we found that the prorenin value is useful solely for predicting development of diabetic retinopathy in adults.
Collapse
Affiliation(s)
- Harumasa Yokota
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| | - Taiji Nagaoka
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| | - Eiichi Sato
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| | - Atsushi Takahashi
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| | - Akito Shimouchi
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| | - Akitoshi Yoshida
- Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
38
|
Huang KH, Hsu BM, Chou MY, Tsai HL, Kao PM, Wang HJ, Hsiao HY, Su MJ, Huang YL. Application of molecular biological techniques to analyze Salmonella seasonal distribution in stream water. FEMS Microbiol Lett 2014; 352:87-96. [PMID: 24417320 DOI: 10.1111/1574-6968.12381] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 12/27/2013] [Accepted: 12/28/2013] [Indexed: 11/28/2022] Open
Abstract
Salmonella is a leading cause of waterborne diseases. Salmonella can survive for a long time in aquatic environments, and its persistence in the environment is of great concern to public health. Nonetheless, the presence and diversity of Salmonella in the aquatic environments in most areas remain relatively unknown. In this study, we examined three analytical processes for an optimum Salmonella detection method, and the optimized method was used to evaluate seasonal variations of Salmonella in aquatic environments. In addition, Salmonella strains were isolated by selective culture medium to identify the serotypes by biochemical testing and serological assay, and to identify the genotypes by pulsed-field gel electrophoresis based on the genetic patterns. A total of 136 water samples were collected in the study area in 9 months. Forty-one (30.1%) samples were found to contain Salmonella-specific invA gene, and most (24/41) of the detections occurred in summer. The serovars of Salmonella enterica were identified, including Bareilly, Isangi, Newport, Paratyphi B var. Java, Potsdam and Typhimurium.
Collapse
Affiliation(s)
- Kuan-Hao Huang
- Department of Earth and Environmental Sciences, National Chung Cheng University, Chiayi, Taiwan, Republic of China
| | | | | | | | | | | | | | | | | |
Collapse
|